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Type II endoleaks after endovascular aneurysm repair are the most common type of endoleak and generate the majority of
secondary interventions. Their natural history is mostly benign, but they can occasionally lead to sac expansion and
eventual rupture. Three-phase computed tomography angiography is the “gold standard” for diagnosis, but duplex ul-
trasound with or without contrast enhancement and magnetic resonance angiography offer an alternative for endoleak
detection or surveillance. Whereas there are concerns as to whether sac expansion can be a dependable marker for risk of
rupture, it is currently the best surrogate available and guides the indication for intervention. Obliteration of type II
endoleaks can be challenging, and a variety of techniques, endovascular, open, and laparoscopic, have been proposed. The
most common approaches are transarterial and translumbar embolization, and they are usually successful, provided the
operator is experienced and persistent, targeting both the branches and the nidus of the endoleak. Recurrences and
subsequent reinterventions should be anticipated, and on continuing sac expansion, repeated endovascular or open
surgical and laparoscopic alternatives may be required. (J Vasc Surg 2014;60:1386-91.)Endovascular aneurysm repair (EVAR) is currently
widely accepted as the standard of care for infrarenal
abdominal aortic aneurysm repair for patients with suitable
anatomy.1-5 The need for serial surveillance and frequent
reinterventions predominantly related to the anticipation
or treatment of endoleaks accounts for its weaknesses and
continues to limit its cost-effectiveness. Whereas there is lit-
tle controversy in the management of type I and type III
endoleaks, type II endoleaks have generated conﬂicting re-
ports about their natural history, detection, and follow-up
and the optimal timing and type of management. This re-
view summarizes the accumulated evidence on type II
endoleaks with particular focus on contemporary detection
strategies, treatment criteria, and technical options (Table).
INCIDENCE AND NATURAL HISTORY
Type II endoleaks are “procedure related” as a result of
patent lumbar arteries or inferior mesenteric artery
branches and may involve various ﬂow patterns.6 They
represent the most frequent type of endoleak, and the inci-
dence has been correlated, although not uniformly, with
the number and size of patent branches before exclu-
sion.7-10 Earlier studies showed possible endograftthe Division of Vascular Surgery, University of Pittsburgh Medical
enter.
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6dependence, but this does not appear to be the case in later
studies with longer follow-up.8,11 The largest published
series comes from the EUROSTAR (European Collabora-
tors on Stent/graft Techniques for aortic Aneurysm
Repair) registry (3595 patients), reporting a 9% rate of
type II endoleak diagnosed any time during follow-up,10
similar to the 8% to 10% rates reported in large systematic
reviews and meta-analyses.5,12,13 The rate is generally
higher at 1 to 6 months and occurs in around 15% of
patients, and although some type II endoleaks may be
identiﬁed at a later date, the prevalence gradually decreases
to <10% at 2 years.8,13 Their natural history is currently
considered relatively benign, and evidence suggests that
approximately 60% of the immediate postoperative type
II endoleaks will resolve spontaneously within 6 months,
whereas the majority of the remaining will continue to
regress over the years.9,14 Factors that have been linked
to spontaneous endoleak resolution are cancer, coronary
and peripheral artery disease, chronic obstructive pulmo-
nary disease, and smoking; long-term anticoagulation
and dual antiplatelet therapies may cause them to
persist.10,14-16 The aneurysm sac may otherwise shrink,
despite the presence of a patent type II endoleak (Fig 1).
Commonly, however, the sac will remain stable, or in about
5.5% to 24%, it will demonstrate enlargement of >5 mm.
The rate of sac enlargement gets even higher, up to 55%,
for endoleaks that persist for >6 months.10,14,17,18
Whereas there is no clear evidence that sac expansion in
this setting is a surrogate for future aneurysm rupture,
aneurysm rupture does occur, although rarely, in patients
with type II endoleaks.4,19 Data from the EUROSTAR
registry on 2463 patients suggested a cumulative 2-year
incidence of rupture after type II endoleak of 1.8% (one
of 55 patients)20; however, this rate was no different in
patients without any detected endoleak (0.9%; ﬁve of 548
Table. Summary of evidence on type II endoleaks
Incidence d 8%-10% overall5,10,12,13
d 15% at 1-6 months after EVAR8,13
d <10% at 2 years after EVAR8,13
d Not device related in current practice8,11
Natural history d Predominantly benign
d 60% resolve within 6 months9,14
d 5.5%-24% will promote sac enlargement10,14,17,18
d For those persisting >6 months, higher rates of sac enlargement (up to 55%) should be anticipated.10,14,17,18
d w1% risk of rupture4,12,19,20
d No evidence that sac enlargement is related to rupture4,12,19,20
Detection d Three-phase CTA is the “gold standard.”
d Contrast-enhanced ultrasound and magnetic resonance angiography may have accuracy equivalent to if not better
than that of CTA. Yet, they are not widely available, and diagnosis is highly operator dependent.21,22
d DUS is the most cost-effective follow-up test and can be used for monitoring aneurysm sac growth. Type II
endoleaks can be differentiated, but diagnosis is highly operator dependent.6,22,24-26
Decision to treat d Lack of robust evidence1,2,12
d Intervention is warranted only on sac enlargement >5 mm but not for endoleak persistence.1,2
Treatment d Endovascular techniques are preferred as minimally invasive.
d Percutaneous transarterial embolization is the most common intervention. Average success rate is 63% (range,
15%-89%).12
d Translumbar embolization is a reasonable alternative, particularly when there is no transarterial access. Average
success rate is 81% (range, 67%-100%).12
d Evidence on ventral or transcaval sac puncture is insufﬁcient.16,27
d Embolization should target the nidus and the feeder branches of the endoleak.12,26,28
d Microcoils are mainly used, but glue, thrombin, and Onyx can also be delivered, with no proven superiority of one
agent over the other.
d Operator should be persistent and cautious to potentially uncover a type I or type III endoleak.19,29,30
d If the endoleak persists and the sac continues to grow after “technically” successful embolizations or when embo-
lization is impossible, more invasive approaches are required.
d Laparotomy or laparoscopy with ligation of the feeding side branches, suturing of the side branch ostia within the
aneurysmal sac, and conversion to open repair are all feasible alternatives that carry higher complexity, morbidity,
and mortality.
CTA, Computed tomography angiography; DUS, duplex ultrasound; EVAR, endovascular aneurysm repair.
Fig 1. After endovascular aneurysm repair (EVAR), the abdominal aortic aneurysm can shrink despite the presence of a
type II endoleak, which may otherwise show late spontaneous resolution. a, Type II endoleak at year 1. b, Persistent
type II endoleak at year 2 with sac shrinkage. c, No endoleak and aneurysm continues to shrink at year 3.
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Sidloff et al (21,744 EVARs, 1515 type II endoleaks),
the rupture rate of all type II endoleaks reviewed was
0.9%; 43% of these ruptures had no sac expansion.12
DETECTION AND FOLLOW-UP
The standard post-EVAR imaging protocols to detect
endoleaks or endograft migration rely on computedtomography angiography (CTA), given its availability and
easy standardization.21 For CTA to properly detect type
II endoleaks, three runs are required, one with and one
without contrast material and a third delayed run during
the venous phase. Duplex ultrasound (DUS) with or
without contrast enhancement and magnetic resonance
angiography have been suggested as alternative imaging
modalities.21,22 Wireless pressure sensors implanted during
Fig 2. Algorithm of type II endoleak management. CEUS, Contrast-enhanced ultrasound; DUS, duplex ultrasound;
EVAR, endovascular aneurysm repair; MRA, magnetic resonance angiography.
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but sufﬁcient data are still lacking.23
DUS is not only cheaper and safer than other modalities
but may actually be more sensitive in the diagnosis of endo-
leaks, although the latter assertion remains controver-
sial.6,22,24-26 Nonetheless, detection of type II endoleaks can
be challenging, and not infrequently they can be missed
(low ﬂow) or may overlap with other types of endoleaks and
cannot be differentiated by any imaging modality. DUS has
the speciﬁc advantage of detecting ﬂow direction of endo-
leaks, facilitating type identiﬁcation, and Doppler waveforms
may even predict the natural history of a type II endoleak.6
Contrast-enhanced ultrasound may have even better
accuracy, particularly in the detection and classiﬁcation of
endoleak.22Unfortunately, accuracy ishighlyoperatordepen-
dent, and technical difﬁculties in patients with large body
habitus still limit its universal application. DUS can be an
excellent test for monitoring the aneurysm sac growth and,
in combination with endoleak evaluation, provides sufﬁcient
data to identify complications requiring intervention.
Post-EVAR surveillance recommendations have under-
gone signiﬁcant updates. Original practice guidelines
included a postoperative 30-day CTA study, repeated at
6months, 1 year, and annually thereafter. There is increasing
evidence to decrease the imaging frequency, to eliminate the
6-month follow-up study, and to substitute CTA beyond or
even at 1 year withDUS.1,2,22,24-26Whereas there is uniform
agreement to generally treat type I or type III endoleaks ondetection, the follow-up protocol remains ill-deﬁned when a
type II endoleak is diagnosed. Although current guidelines
suggest CTA at 6 months on type II endoleak detection at
the postoperative CTA study,1,2 accumulating evidence sug-
gests omission of this follow-up visit and repeated imaging at
12 months with either CTA or DUS (combined with radio-
graphs) or non-contrast-enhanced computed tomography
to check for sac growth with subsequent annual DUS, pro-
vided the sac does not expand.24-26 Such DUS follow-up
protocols should be implemented only in accredited vascular
laboratories with experienced technologists and internal
quality controls.
MANAGEMENT
Decision to treat a type II endoleak. On the basis of
their benign natural history and very rare association with
rupture (w1%), the decision to treat a type II endoleak has
changed steadily over the years, gradually favoring a more
conservative approach. Criteria for intervention vary across
the literature; the most common have been a persistent type
II endoleak or an associated sac expansion >5 mm.12
Whereas there are concerns as to whether sac expansion can
be a surrogate marker for risk of rupture, this is currently the
best guide available; thus, intervention is warranted only on
sac enlargement but not for endoleak persistence alone.1,2 A
treatment algorithm is summarized in Fig 2.
Treatment of a type II endoleak. Obliteration of type
II endoleaks can be difﬁcult. The principle of treatment is
Fig 3. Transarterial embolization. a, A 6F sheath has been placed in the internal iliac artery, and a 5F selective catheter
is used to image the endoleak. b, A microcatheter is guided over a microwire (coaxial system) toward the lumbar artery
origin. c, Microcoils are used, and there is no residual endoleak. d, Six months later, the endoleak persists and the
abdominal aortic aneurysm is expanding; more feeders are identiﬁed (arrow). e, The microcatheter is again used to
reach the abdominal aortic aneurysm sac. f, Nidus and branches are coiled and endoleak resolves.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 5 Avgerinos et al 1389to eliminate the branches at their junction with the aneu-
rysm. A variety of endovascular, open, and laparoscopic
techniques have been proposed to abolish side branch
perfusion. Whereas all alternatives may have a role, endo-
vascular techniques are preferred, given their minimally
invasive nature.
Percutaneous transarterial embolization is the most
common intervention for type II endoleaks. Targeting to
embolize the nidus and the feeder branches of the endoleak,
transfemoral or transbrachial access is obtained and a coaxial
system with microcatheters is created to reach the inferior
mesenteric or lumbar arteries; proximal lumbar arteries
may be difﬁcult to reach. The approach is generally feasible
through the internal iliac (superior gluteal) or superior
mesenteric (middle colic and marginal) arteries, depending
on the target and the respective collateralization (Fig 3).
Microcoils are mainly used, but glue, thrombin, and Onyx
(ethylene vinylealcohol copolymer) can also be delivered,
with no proven superiority of one agent over the other.
Translumbar embolization is a reasonable alternative,
particularly when there is no transarterial access (occluded
internal iliac or inferior mesenteric arteries, prior transarte-
rial embolization) left. Given the rarity of the technique,not all vascular surgeons are familiar, so some technical de-
tails merit attention, despite several variations.16,27-30 The
endoleak is identiﬁed on prior computed tomography scans
and referenced to ﬂuoroscopic landmarks (eg, localization
of the endoleak to speciﬁc vertebral bodies or radiopaque
markers on the stent graft). With the patient in prone po-
sition, access is obtained under ﬂuoroscopy, typically from
a left paraspinal approach (w4 ﬁngerbreadths from
midline). Over a wire, a 6F 30-cm sheath is introduced,
and following a sacogram, the system is positioned directly
within the endoleak, which is signaled with brisk blood re-
turn. Subsequently, similar to the transarterial approach, a
coaxial system with microcatheters is created to reach the
nidus and the target arteries (Fig 4). Some authors have
also suggested ventral or transcaval sac puncture, but data
are still insufﬁcient.16,31
In the most recent systematic review, the success rate,
deﬁned as no recurrence during follow-up, averages
62.5% (range, 15%-89%) for the transarterial approach (120
reviewed interventions; average follow-up, 4-25 months)
and81% (range, 67%-100%) for the translumbar (57 interven-
tions; average follow-up, 3-22 months).12 All studies that
compare transarterial with translumbar approaches show
Fig 4. Translumbar embolization. a,With the patient in the prone position, access has been obtained through the left
paraspinal approach, and a 6F 30-cm sheath has been introduced into the abdominal aortic aneurysm sac. b, A
sacogram is obtained that reveals the endoleak. c, A 5F catheter is used to guide embolization. d, The nidus is
embolized with multiple coils.
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majority of cases, translumbar was a second-line treatment,
after the transarterial had failed; thus, such comparisons
may not be valid. A more important aspect of success, irre-
spective of approach taken, is gaining access and embolizing
the sac (nidus) and as many feeders (inﬂow and outﬂow)
as possible, a task requiring advanced endovascular
skills.12,26,27 It should otherwise be expected that recur-
rences and subsequent reinterventions are going to be
frequent, the sac may continue to grow, and even occult
type I or type III endoleaks may be revealed up to 5 years
after EVAR; thus, the operator needs to be cautious and
persistent.19,32,33 Should the endoleak persist and the sac
continue to grow after a “technically” successful emboliza-
tion or when embolization is impossible, more invasive ap-
proaches are required. Laparotomy or laparoscopy with
ligation of the feeding side branches, suturing of the side
branch ostia within the aneurysmal sac but leaving the stent
graft intact, and ﬁnally conversion to open repair are allfeasible alternatives that carry higher complexity, morbidity,
and mortality.
CONCLUSIONS
The natural history of type II endoleaks has been recog-
nized as predominantly benign. DUS can detect endoleaks,
but three-phase CTA remains the “gold standard” for accu-
rate diagnosis and eventual treatment planning on sac
expansion. The most common approaches are transarterial
and translumbar embolization, and they are usually success-
ful but often require persistence and advanced endovascular
skills. Access and embolization of both the ﬂow channel and
the nidus are essential for a successful outcome.
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